NRIX Stock Clocks Worst Day Ever After Sanofi Discontinues Trial Of Licensed Drug: Wells Fargo Slashes Price Target
Paris-headquartered Sanofi notified Nurix on Tuesday that it is ending the early-stage first-in-human trial of SAR448272 and terminating the program entirely.